| Conditionally active polypeptides |
2022-8-19 |
2022-12-22 |
|
| Conditionally active anti-her2 antibodies, antibody fragments their … |
2022-7-18 |
2022-9-01 |
|
| Comprehensive monoclonal antibody generation |
2022-6-22 |
2022-12-08 |
|
| Express humanization of antibodies |
2022-6-21 |
2022-10-13 |
|
| Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses … |
2022-6-15 |
2022-6-30 |
|
| Protein therapeutics for treatment of senescent cells |
2022-5-16 |
2022-9-08 |
|
| Anti-Axl antibodies, antibody fragments and their immunoconjugates and uses … |
2022-5-13 |
2022-6-02 |
|
| Mirac proteins |
2022-4-27 |
2022-8-09 |
|
| Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses … |
2022-3-30 |
2022-7-06 |
|
| Humanized anti-CD73 antibody |
2022-3-29 |
2022-7-12 |
|
| Conditionally active polypeptides and methods for generating same |
2022-3-15 |
2022-6-28 |
|
| Proteins targeting orthologs |
2022-2-24 |
2022-10-27 |
|
| Conditionally active biological proteins |
2022-1-11 |
2022-4-28 |
|
| Combination therapies comprising antibody molecules to pd-1 |
2021-12-13 |
2023-1-19 |
|
| Conditionally active anti-epcam antibodies, antibody fragments, their … |
2021-12-07 |
2022-2-01 |
|
| Methods of treating axl-exrpressing cancers with anti-axl antibodies, antibody … |
2021-11-12 |
2022-7-16 |
|
| Conditionally active chimeric antigen receptors for modified t-cells |
2021-7-30 |
2021-11-18 |
|
| Conditionally active anti-cd46 antibodies, antibody fragments, their … |
2021-6-18 |
2022-4-16 |
|
| Conditionally active anti-nectin-4 antibodies |
2021-6-18 |
2022-2-01 |
|
| Conditionally active chimeric antigen receptors for modified T-cells |
2021-6-16 |
2021-7-08 |
|
| Simultaneous, Integrated Selection and Evolution of Antibody/Protein … |
2021-5-19 |
2021-6-10 |
|
| Mirac Proteins |
2021-4-01 |
2023-3-09 |
2023-3-09 |
| Chimeric antigen receptors to her2 and methods of use thereof |
2021-1-23 |
2022-11-16 |
|
| Conditionally active anti-HER 2 antibodies, antibody fragments, … |
2021-1-22 |
2023-4-07 |
|
| Multi-specific antibody constructs |
2020-12-13 |
2021-1-31 |
|
| Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses … |
2020-11-30 |
2021-1-31 |
|
| Novel methods of protein evolution |
2020-9-30 |
2021-1-21 |
|
| Multi-specific monoclonal antibodies |
2020-3-25 |
2023-2-16 |
2023-2-16 |
| Discovering and producing conditionally active biologic proteins in the same … |
2019-10-31 |
2020-7-09 |
|
| Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses … |
2019-10-25 |
2022-8-26 |
|
| Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses … |
2019-10-25 |
2023-1-03 |
2023-1-03 |
| Conditionally active chimeric antigen receptors for modified t-cells |
2019-8-23 |
2021-7-14 |
|
| Conditionally active protein with pH selectivity |
2019-8-20 |
2021-3-26 |
|
| Conditionally Active Biological Proteins |
2019-5-28 |
2019-9-19 |
|
| Modified antibody regions and uses thereof |
2019-4-01 |
2021-2-11 |
2021-2-11 |
| Novel methods of protein evolution |
2018-9-04 |
2020-10-15 |
2020-10-15 |
| Chimeric antigen receptors against Axl or Ror2 and methods of use thereof |
2018-1-17 |
2019-7-18 |
|
| Anti-cd22 antibodies |
2017-12-11 |
2018-3-29 |
|
| Antibody molecules to lag-3 and uses thereof |
2017-3-24 |
2017-7-27 |
|
| Diagnostics using conditionally active antibodies |
2017-1-11 |
2017-7-13 |
|
| Diagnostic methods using conditionally active antibodies |
2017-1-10 |
2022-9-13 |
2022-9-13 |
| Proteins targeting orthologs |
2015-1-07 |
2023-4-04 |
2023-4-04 |
| Temperature sensitive mutants of matrix metalloproteases and uses thereof |
2010-3-05 |
2011-9-22 |
|
| Humanized anti-il-6 antibodies |
2009-11-13 |
2010-6-03 |
|
| 条件性活性抗her2抗体、抗体片段、其免疫结合物及其用途 |
2021-1-22 |
2023-4-07 |
|
| Orthologues ciblant les proteines |
2015-1-07 |
2023-4-04 |
2023-4-04 |